23:07 , Nov 2, 2016 |  BC Week In Review  |  Clinical News

AMC303: Ph I/Ib started

amcure began an open-label, dose-escalation, dose-expansion, European Phase I/Ib trial to evaluate AMC303 in up to 50 patients. amcure GmbH, Eggenstein-Leopoldshafen, Germany  Product: AMC303  Business: Cancer  Molecular target: Splice variant v6 of CD44 (CD44v6)  Description: Peptide inhibitor of CDD44v6  Indication: Treat...